Loading…

Exploring SARS-COV-2 structural proteins to design a multi-epitope vaccine using immunoinformatics approach: An in silico study

In December 2019, a new virus called SARS-CoV-2 was reported in China and quickly spread to other parts of the world. The development of SARS-COV-2 vaccines has recently received much attention from numerous researchers. The present study aims to design an effective multi-epitope vaccine against SAR...

Full description

Saved in:
Bibliographic Details
Published in:Computers in biology and medicine 2021-06, Vol.133, p.104390-104390, Article 104390
Main Authors: Sanami, Samira, Alizadeh, Morteza, Nosrati, Masoud, Dehkordi, Korosh Ashrafi, Azadegan-Dehkordi, Fatemeh, Tahmasebian, Shahram, Nosrati, Hamed, Arjmand, Mohammad-Hassan, Ghasemi-Dehnoo, Maryam, Rafiei, Ali, Bagheri, Nader
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c507t-6d87da6fd0a99d47967218d8d7be789a4f926e3200933ef54a27202e029a1a433
cites cdi_FETCH-LOGICAL-c507t-6d87da6fd0a99d47967218d8d7be789a4f926e3200933ef54a27202e029a1a433
container_end_page 104390
container_issue
container_start_page 104390
container_title Computers in biology and medicine
container_volume 133
creator Sanami, Samira
Alizadeh, Morteza
Nosrati, Masoud
Dehkordi, Korosh Ashrafi
Azadegan-Dehkordi, Fatemeh
Tahmasebian, Shahram
Nosrati, Hamed
Arjmand, Mohammad-Hassan
Ghasemi-Dehnoo, Maryam
Rafiei, Ali
Bagheri, Nader
description In December 2019, a new virus called SARS-CoV-2 was reported in China and quickly spread to other parts of the world. The development of SARS-COV-2 vaccines has recently received much attention from numerous researchers. The present study aims to design an effective multi-epitope vaccine against SARS-COV-2 using the reverse vaccinology method. In this regard, structural proteins from SARS-COV-2, including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, were selected as target antigens for epitope prediction. A total of five helper T lymphocytes (HTL) and five cytotoxic T lymphocytes (CTL) epitopes were selected after screening the predicted epitopes for antigenicity, allergenicity, and toxicity. Subsequently, the selected HTL and CTL epitopes were fused via flexible linkers. Next, the cholera toxin B-subunit (CTxB) as an adjuvant was linked to the N-terminal of the chimeric structure. The proposed vaccine was analyzed for the properties of physicochemical, antigenicity, and allergenicity. The 3D model of the vaccine construct was predicted and docked with the Toll-like receptor 4 (TLR4). The molecular dynamics (MD) simulation was performed to evaluate the stable interactions between the vaccine construct and TLR4. The immune simulation was also conducted to explore the immune responses induced by the vaccine. Finally, in silico cloning of the vaccine construct into the pET-28 (+) vector was conducted. The results obtained from all bioinformatics analysis stages were satisfactory; however, in vitro and in vivo tests are essential to validate these results. •To design a multi-epitope vaccine against SARS-COV-2, we used a set of bioinformatics approaches.•The vaccine was designed using several epitopes, adjuvant, and appropriate linkers.•The prediction of secondary and 3D models of the vaccine was conducted.•The molecular docking, MD simulation, immune simulation was performed.•Our results indicated that the vaccine could be proposed as vaccine candidate against SARS-COV-2.
doi_str_mv 10.1016/j.compbiomed.2021.104390
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8055380</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010482521001840</els_id><sourcerecordid>2518741446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-6d87da6fd0a99d47967218d8d7be789a4f926e3200933ef54a27202e029a1a433</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhSMEokPhLyBLbNhkuH4ksVkgDaPykCpVaoGt5bGdqUeJHWxnRFf8dTya0hY2XVmyv3uuzzlVhTAsMeD23W6pwzhtXBitWRIguFwzKuBJtcC8EzU0lD2tFgAYasZJc1K9SGkHAAwoPK9OKOWiYY1YVL_Pfk1DiM5v0dXq8qpeX_yoCUo5zjrPUQ1oiiFb5xPKARmb3NYjhcZ5yK62k8thsmivtHbeojkdZNw4zj4434c4qux0QmoqIkpfv0crj5xHyQ1Oh7JkNjcvq2e9GpJ9dXueVt8_nX1bf6nPLz5_Xa_Oa91Al-vW8M6otjeghDCsE21HMDfcdBvbcaFYL0hrKQEQlNq-YYp0JRcLRCisGKWn1Yej7jRvSmja-lzcySm6UcUbGZST_754dy23YS85NA3lUATe3grE8HO2KcvRJW2HQXkb5iRJU5JnmLG2oG_-Q3dhjr7YKxSlpMMt4YXiR0rHkFK0_d1nMMhDy3In71uWh5blseUy-vqhmbvBv7UW4OMRsCXSvbNRJu2s19a4aHWWJrjHt_wBKny_bw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2533271628</pqid></control><display><type>article</type><title>Exploring SARS-COV-2 structural proteins to design a multi-epitope vaccine using immunoinformatics approach: An in silico study</title><source>ScienceDirect Journals</source><creator>Sanami, Samira ; Alizadeh, Morteza ; Nosrati, Masoud ; Dehkordi, Korosh Ashrafi ; Azadegan-Dehkordi, Fatemeh ; Tahmasebian, Shahram ; Nosrati, Hamed ; Arjmand, Mohammad-Hassan ; Ghasemi-Dehnoo, Maryam ; Rafiei, Ali ; Bagheri, Nader</creator><creatorcontrib>Sanami, Samira ; Alizadeh, Morteza ; Nosrati, Masoud ; Dehkordi, Korosh Ashrafi ; Azadegan-Dehkordi, Fatemeh ; Tahmasebian, Shahram ; Nosrati, Hamed ; Arjmand, Mohammad-Hassan ; Ghasemi-Dehnoo, Maryam ; Rafiei, Ali ; Bagheri, Nader</creatorcontrib><description>In December 2019, a new virus called SARS-CoV-2 was reported in China and quickly spread to other parts of the world. The development of SARS-COV-2 vaccines has recently received much attention from numerous researchers. The present study aims to design an effective multi-epitope vaccine against SARS-COV-2 using the reverse vaccinology method. In this regard, structural proteins from SARS-COV-2, including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, were selected as target antigens for epitope prediction. A total of five helper T lymphocytes (HTL) and five cytotoxic T lymphocytes (CTL) epitopes were selected after screening the predicted epitopes for antigenicity, allergenicity, and toxicity. Subsequently, the selected HTL and CTL epitopes were fused via flexible linkers. Next, the cholera toxin B-subunit (CTxB) as an adjuvant was linked to the N-terminal of the chimeric structure. The proposed vaccine was analyzed for the properties of physicochemical, antigenicity, and allergenicity. The 3D model of the vaccine construct was predicted and docked with the Toll-like receptor 4 (TLR4). The molecular dynamics (MD) simulation was performed to evaluate the stable interactions between the vaccine construct and TLR4. The immune simulation was also conducted to explore the immune responses induced by the vaccine. Finally, in silico cloning of the vaccine construct into the pET-28 (+) vector was conducted. The results obtained from all bioinformatics analysis stages were satisfactory; however, in vitro and in vivo tests are essential to validate these results. •To design a multi-epitope vaccine against SARS-COV-2, we used a set of bioinformatics approaches.•The vaccine was designed using several epitopes, adjuvant, and appropriate linkers.•The prediction of secondary and 3D models of the vaccine was conducted.•The molecular docking, MD simulation, immune simulation was performed.•Our results indicated that the vaccine could be proposed as vaccine candidate against SARS-COV-2.</description><identifier>ISSN: 0010-4825</identifier><identifier>ISSN: 1879-0534</identifier><identifier>EISSN: 1879-0534</identifier><identifier>DOI: 10.1016/j.compbiomed.2021.104390</identifier><identifier>PMID: 33895459</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Algorithms ; Allergenicity ; Amino acids ; Antigenicity ; Antigens ; Biocompatibility ; Bioinformatics ; Biomedical materials ; China ; Cholera ; Cholera toxin ; Cholera toxin B subunit ; Cloning ; Cloning vectors ; Coronaviruses ; COVID-19 ; COVID-19 Vaccines ; CTxB ; Cytokines ; Cytotoxicity ; Disease transmission ; Epitope ; Epitopes ; Epitopes, B-Lymphocyte ; Epitopes, T-Lymphocyte ; Genomes ; Humans ; Immune response ; In vivo methods and tests ; Infections ; Lymphocytes ; Lymphocytes T ; Machine learning ; Microorganisms ; Molecular Docking Simulation ; Molecular dynamics ; Molecular weight ; Nucleocapsids ; Pathogens ; Peptides ; Proteins ; Reverse vaccinology ; SARS-COV-2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Simulation ; Structural proteins ; Three dimensional models ; TLR4 protein ; Toll-like receptors ; Toxicity ; Toxins ; Vaccine ; Vaccines ; Vaccines, Subunit ; Viruses ; Waterborne diseases</subject><ispartof>Computers in biology and medicine, 2021-06, Vol.133, p.104390-104390, Article 104390</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><rights>2021. Elsevier Ltd</rights><rights>2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-6d87da6fd0a99d47967218d8d7be789a4f926e3200933ef54a27202e029a1a433</citedby><cites>FETCH-LOGICAL-c507t-6d87da6fd0a99d47967218d8d7be789a4f926e3200933ef54a27202e029a1a433</cites><orcidid>0000-0003-4214-6502 ; 0000-0002-6952-1109 ; 0000-0001-9348-2405</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33895459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanami, Samira</creatorcontrib><creatorcontrib>Alizadeh, Morteza</creatorcontrib><creatorcontrib>Nosrati, Masoud</creatorcontrib><creatorcontrib>Dehkordi, Korosh Ashrafi</creatorcontrib><creatorcontrib>Azadegan-Dehkordi, Fatemeh</creatorcontrib><creatorcontrib>Tahmasebian, Shahram</creatorcontrib><creatorcontrib>Nosrati, Hamed</creatorcontrib><creatorcontrib>Arjmand, Mohammad-Hassan</creatorcontrib><creatorcontrib>Ghasemi-Dehnoo, Maryam</creatorcontrib><creatorcontrib>Rafiei, Ali</creatorcontrib><creatorcontrib>Bagheri, Nader</creatorcontrib><title>Exploring SARS-COV-2 structural proteins to design a multi-epitope vaccine using immunoinformatics approach: An in silico study</title><title>Computers in biology and medicine</title><addtitle>Comput Biol Med</addtitle><description>In December 2019, a new virus called SARS-CoV-2 was reported in China and quickly spread to other parts of the world. The development of SARS-COV-2 vaccines has recently received much attention from numerous researchers. The present study aims to design an effective multi-epitope vaccine against SARS-COV-2 using the reverse vaccinology method. In this regard, structural proteins from SARS-COV-2, including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, were selected as target antigens for epitope prediction. A total of five helper T lymphocytes (HTL) and five cytotoxic T lymphocytes (CTL) epitopes were selected after screening the predicted epitopes for antigenicity, allergenicity, and toxicity. Subsequently, the selected HTL and CTL epitopes were fused via flexible linkers. Next, the cholera toxin B-subunit (CTxB) as an adjuvant was linked to the N-terminal of the chimeric structure. The proposed vaccine was analyzed for the properties of physicochemical, antigenicity, and allergenicity. The 3D model of the vaccine construct was predicted and docked with the Toll-like receptor 4 (TLR4). The molecular dynamics (MD) simulation was performed to evaluate the stable interactions between the vaccine construct and TLR4. The immune simulation was also conducted to explore the immune responses induced by the vaccine. Finally, in silico cloning of the vaccine construct into the pET-28 (+) vector was conducted. The results obtained from all bioinformatics analysis stages were satisfactory; however, in vitro and in vivo tests are essential to validate these results. •To design a multi-epitope vaccine against SARS-COV-2, we used a set of bioinformatics approaches.•The vaccine was designed using several epitopes, adjuvant, and appropriate linkers.•The prediction of secondary and 3D models of the vaccine was conducted.•The molecular docking, MD simulation, immune simulation was performed.•Our results indicated that the vaccine could be proposed as vaccine candidate against SARS-COV-2.</description><subject>Algorithms</subject><subject>Allergenicity</subject><subject>Amino acids</subject><subject>Antigenicity</subject><subject>Antigens</subject><subject>Biocompatibility</subject><subject>Bioinformatics</subject><subject>Biomedical materials</subject><subject>China</subject><subject>Cholera</subject><subject>Cholera toxin</subject><subject>Cholera toxin B subunit</subject><subject>Cloning</subject><subject>Cloning vectors</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>CTxB</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Disease transmission</subject><subject>Epitope</subject><subject>Epitopes</subject><subject>Epitopes, B-Lymphocyte</subject><subject>Epitopes, T-Lymphocyte</subject><subject>Genomes</subject><subject>Humans</subject><subject>Immune response</subject><subject>In vivo methods and tests</subject><subject>Infections</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Machine learning</subject><subject>Microorganisms</subject><subject>Molecular Docking Simulation</subject><subject>Molecular dynamics</subject><subject>Molecular weight</subject><subject>Nucleocapsids</subject><subject>Pathogens</subject><subject>Peptides</subject><subject>Proteins</subject><subject>Reverse vaccinology</subject><subject>SARS-COV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Simulation</subject><subject>Structural proteins</subject><subject>Three dimensional models</subject><subject>TLR4 protein</subject><subject>Toll-like receptors</subject><subject>Toxicity</subject><subject>Toxins</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, Subunit</subject><subject>Viruses</subject><subject>Waterborne diseases</subject><issn>0010-4825</issn><issn>1879-0534</issn><issn>1879-0534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkUtv1DAUhSMEokPhLyBLbNhkuH4ksVkgDaPykCpVaoGt5bGdqUeJHWxnRFf8dTya0hY2XVmyv3uuzzlVhTAsMeD23W6pwzhtXBitWRIguFwzKuBJtcC8EzU0lD2tFgAYasZJc1K9SGkHAAwoPK9OKOWiYY1YVL_Pfk1DiM5v0dXq8qpeX_yoCUo5zjrPUQ1oiiFb5xPKARmb3NYjhcZ5yK62k8thsmivtHbeojkdZNw4zj4434c4qux0QmoqIkpfv0crj5xHyQ1Oh7JkNjcvq2e9GpJ9dXueVt8_nX1bf6nPLz5_Xa_Oa91Al-vW8M6otjeghDCsE21HMDfcdBvbcaFYL0hrKQEQlNq-YYp0JRcLRCisGKWn1Yej7jRvSmja-lzcySm6UcUbGZST_754dy23YS85NA3lUATe3grE8HO2KcvRJW2HQXkb5iRJU5JnmLG2oG_-Q3dhjr7YKxSlpMMt4YXiR0rHkFK0_d1nMMhDy3In71uWh5blseUy-vqhmbvBv7UW4OMRsCXSvbNRJu2s19a4aHWWJrjHt_wBKny_bw</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Sanami, Samira</creator><creator>Alizadeh, Morteza</creator><creator>Nosrati, Masoud</creator><creator>Dehkordi, Korosh Ashrafi</creator><creator>Azadegan-Dehkordi, Fatemeh</creator><creator>Tahmasebian, Shahram</creator><creator>Nosrati, Hamed</creator><creator>Arjmand, Mohammad-Hassan</creator><creator>Ghasemi-Dehnoo, Maryam</creator><creator>Rafiei, Ali</creator><creator>Bagheri, Nader</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AL</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>JQ2</scope><scope>K7-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0N</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4214-6502</orcidid><orcidid>https://orcid.org/0000-0002-6952-1109</orcidid><orcidid>https://orcid.org/0000-0001-9348-2405</orcidid></search><sort><creationdate>20210601</creationdate><title>Exploring SARS-COV-2 structural proteins to design a multi-epitope vaccine using immunoinformatics approach: An in silico study</title><author>Sanami, Samira ; Alizadeh, Morteza ; Nosrati, Masoud ; Dehkordi, Korosh Ashrafi ; Azadegan-Dehkordi, Fatemeh ; Tahmasebian, Shahram ; Nosrati, Hamed ; Arjmand, Mohammad-Hassan ; Ghasemi-Dehnoo, Maryam ; Rafiei, Ali ; Bagheri, Nader</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-6d87da6fd0a99d47967218d8d7be789a4f926e3200933ef54a27202e029a1a433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Algorithms</topic><topic>Allergenicity</topic><topic>Amino acids</topic><topic>Antigenicity</topic><topic>Antigens</topic><topic>Biocompatibility</topic><topic>Bioinformatics</topic><topic>Biomedical materials</topic><topic>China</topic><topic>Cholera</topic><topic>Cholera toxin</topic><topic>Cholera toxin B subunit</topic><topic>Cloning</topic><topic>Cloning vectors</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>CTxB</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Disease transmission</topic><topic>Epitope</topic><topic>Epitopes</topic><topic>Epitopes, B-Lymphocyte</topic><topic>Epitopes, T-Lymphocyte</topic><topic>Genomes</topic><topic>Humans</topic><topic>Immune response</topic><topic>In vivo methods and tests</topic><topic>Infections</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Machine learning</topic><topic>Microorganisms</topic><topic>Molecular Docking Simulation</topic><topic>Molecular dynamics</topic><topic>Molecular weight</topic><topic>Nucleocapsids</topic><topic>Pathogens</topic><topic>Peptides</topic><topic>Proteins</topic><topic>Reverse vaccinology</topic><topic>SARS-COV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Simulation</topic><topic>Structural proteins</topic><topic>Three dimensional models</topic><topic>TLR4 protein</topic><topic>Toll-like receptors</topic><topic>Toxicity</topic><topic>Toxins</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, Subunit</topic><topic>Viruses</topic><topic>Waterborne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanami, Samira</creatorcontrib><creatorcontrib>Alizadeh, Morteza</creatorcontrib><creatorcontrib>Nosrati, Masoud</creatorcontrib><creatorcontrib>Dehkordi, Korosh Ashrafi</creatorcontrib><creatorcontrib>Azadegan-Dehkordi, Fatemeh</creatorcontrib><creatorcontrib>Tahmasebian, Shahram</creatorcontrib><creatorcontrib>Nosrati, Hamed</creatorcontrib><creatorcontrib>Arjmand, Mohammad-Hassan</creatorcontrib><creatorcontrib>Ghasemi-Dehnoo, Maryam</creatorcontrib><creatorcontrib>Rafiei, Ali</creatorcontrib><creatorcontrib>Bagheri, Nader</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Computing Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Computer Science Collection</collection><collection>Computer Science Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Computing Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Computers in biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanami, Samira</au><au>Alizadeh, Morteza</au><au>Nosrati, Masoud</au><au>Dehkordi, Korosh Ashrafi</au><au>Azadegan-Dehkordi, Fatemeh</au><au>Tahmasebian, Shahram</au><au>Nosrati, Hamed</au><au>Arjmand, Mohammad-Hassan</au><au>Ghasemi-Dehnoo, Maryam</au><au>Rafiei, Ali</au><au>Bagheri, Nader</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring SARS-COV-2 structural proteins to design a multi-epitope vaccine using immunoinformatics approach: An in silico study</atitle><jtitle>Computers in biology and medicine</jtitle><addtitle>Comput Biol Med</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>133</volume><spage>104390</spage><epage>104390</epage><pages>104390-104390</pages><artnum>104390</artnum><issn>0010-4825</issn><issn>1879-0534</issn><eissn>1879-0534</eissn><abstract>In December 2019, a new virus called SARS-CoV-2 was reported in China and quickly spread to other parts of the world. The development of SARS-COV-2 vaccines has recently received much attention from numerous researchers. The present study aims to design an effective multi-epitope vaccine against SARS-COV-2 using the reverse vaccinology method. In this regard, structural proteins from SARS-COV-2, including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, were selected as target antigens for epitope prediction. A total of five helper T lymphocytes (HTL) and five cytotoxic T lymphocytes (CTL) epitopes were selected after screening the predicted epitopes for antigenicity, allergenicity, and toxicity. Subsequently, the selected HTL and CTL epitopes were fused via flexible linkers. Next, the cholera toxin B-subunit (CTxB) as an adjuvant was linked to the N-terminal of the chimeric structure. The proposed vaccine was analyzed for the properties of physicochemical, antigenicity, and allergenicity. The 3D model of the vaccine construct was predicted and docked with the Toll-like receptor 4 (TLR4). The molecular dynamics (MD) simulation was performed to evaluate the stable interactions between the vaccine construct and TLR4. The immune simulation was also conducted to explore the immune responses induced by the vaccine. Finally, in silico cloning of the vaccine construct into the pET-28 (+) vector was conducted. The results obtained from all bioinformatics analysis stages were satisfactory; however, in vitro and in vivo tests are essential to validate these results. •To design a multi-epitope vaccine against SARS-COV-2, we used a set of bioinformatics approaches.•The vaccine was designed using several epitopes, adjuvant, and appropriate linkers.•The prediction of secondary and 3D models of the vaccine was conducted.•The molecular docking, MD simulation, immune simulation was performed.•Our results indicated that the vaccine could be proposed as vaccine candidate against SARS-COV-2.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>33895459</pmid><doi>10.1016/j.compbiomed.2021.104390</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-4214-6502</orcidid><orcidid>https://orcid.org/0000-0002-6952-1109</orcidid><orcidid>https://orcid.org/0000-0001-9348-2405</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0010-4825
ispartof Computers in biology and medicine, 2021-06, Vol.133, p.104390-104390, Article 104390
issn 0010-4825
1879-0534
1879-0534
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8055380
source ScienceDirect Journals
subjects Algorithms
Allergenicity
Amino acids
Antigenicity
Antigens
Biocompatibility
Bioinformatics
Biomedical materials
China
Cholera
Cholera toxin
Cholera toxin B subunit
Cloning
Cloning vectors
Coronaviruses
COVID-19
COVID-19 Vaccines
CTxB
Cytokines
Cytotoxicity
Disease transmission
Epitope
Epitopes
Epitopes, B-Lymphocyte
Epitopes, T-Lymphocyte
Genomes
Humans
Immune response
In vivo methods and tests
Infections
Lymphocytes
Lymphocytes T
Machine learning
Microorganisms
Molecular Docking Simulation
Molecular dynamics
Molecular weight
Nucleocapsids
Pathogens
Peptides
Proteins
Reverse vaccinology
SARS-COV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Simulation
Structural proteins
Three dimensional models
TLR4 protein
Toll-like receptors
Toxicity
Toxins
Vaccine
Vaccines
Vaccines, Subunit
Viruses
Waterborne diseases
title Exploring SARS-COV-2 structural proteins to design a multi-epitope vaccine using immunoinformatics approach: An in silico study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A42%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20SARS-COV-2%20structural%20proteins%20to%20design%20a%20multi-epitope%20vaccine%20using%20immunoinformatics%20approach:%20An%20in%20silico%20study&rft.jtitle=Computers%20in%20biology%20and%20medicine&rft.au=Sanami,%20Samira&rft.date=2021-06-01&rft.volume=133&rft.spage=104390&rft.epage=104390&rft.pages=104390-104390&rft.artnum=104390&rft.issn=0010-4825&rft.eissn=1879-0534&rft_id=info:doi/10.1016/j.compbiomed.2021.104390&rft_dat=%3Cproquest_pubme%3E2518741446%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c507t-6d87da6fd0a99d47967218d8d7be789a4f926e3200933ef54a27202e029a1a433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2533271628&rft_id=info:pmid/33895459&rfr_iscdi=true